Stay updated with breaking news from Calt story. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HC Wainwright reaffirmed their buy rating on shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Free Report) in a research report report published on Monday, Benzinga reports. The brokerage currently has a $50.00 price objective on the stock. Separately, Guggenheim lowered their target price on Calliditas Therapeutics AB (publ) from $21.00 to $18.00 and set […] ....
HC Wainwright reaffirmed their buy rating on shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Free Report) in a report published on Monday, Benzinga reports. HC Wainwright currently has a $50.00 price target on the stock. Separately, Guggenheim decreased their price objective on Calliditas Therapeutics AB (publ) from $21.00 to $18.00 and set a neutral […] ....
Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Free Report) was the recipient of a significant increase in short interest in September. As of September 30th, there was short interest totalling 3,800 shares, an increase of 40.7% from the September 15th total of 2,700 shares. Based on an average trading volume of 8,900 shares, the days-to-cover […] ....
Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Free Report)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $18.90, but opened at $18.26. Calliditas Therapeutics AB (publ) shares last traded at $18.02, with a volume of 552 shares traded. Analysts Set New Price Targets CALT has been the […] ....
Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Free Report) shares gapped up before the market opened on Thursday . The stock had previously closed at $17.70, but opened at $18.94. Calliditas Therapeutics AB (publ) shares last traded at $18.69, with a volume of 2,285 shares changing hands. Analysts Set New Price Targets Several equities research […] ....